Venetoclax, Obinutuzumab Improved HRQoL in CLL Despite Existing Geriatric Impairments
Frontline fixed-duration venetoclax plus obinutuzumab improved patient-reported outcomes and quality of life in older patients with chronic lymphocytic leukemia ...
Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL
The triple combination of obinutuzumab, ibrutinib, and venetoclax has shown a relatively high response rate among previously untreated patients with high-risk chronic lymphocytic leukemia ...
Results from Combination Trial in Older Adults with Treatment-Naïve CLL Confounded by COVID-Related Deaths
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib combined with obinutuzumab, an anti-CD20 antibody, is a standard regimen used to treat newly diagnosed ...
Are Hypomethylating Agents the Best First-Line Choice for Treating CMML?
The U.S. Food and Drug Administration has approved two hypomethylating agents (HMAs), azacitidine and decitabine, for the treatment of chronic myelomonocytic leukemia ...
Studies Provide Insights Into BTK Inhibitor Resistance
The development and regulatory approval of covalent Bruton tyrosine kinase (BTK) inhibitors changed the treatment landscape for chronic lymphocytic leukemia ...
Early MMR With TKI Therapy Not Necessary to Normalize Survival in Patients Over 60 With CML
Achieving a major molecular response (MMR) within the first two years of initiating tyrosine kinase inhibitor (TKI) therapy has been associated with higher chances of deep and durable molecular responses ...
Decitabine Yields Similar Survival Despite Superior Responses Versus HU in MP-CMML
Despite superior response rates, the hypomethylating agent (HMA) decitabine did not produce event-free survival (EFS) rates that were better than hydroxyurea (HU) in patients with advanced myeloproliferative chronic myelomonocytic leukemia ...
Vemurafenib Retreatment Deemed Effective in R/R Hairy Cell Leukemia
Frequent relapses after vemurafenib monotherapy in the R/R HCL setting may be from persistent residual disease after a limited duration of treatment ...
Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19
Because patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a subtype of NHL, have both a higher risk of poor outcomes from COVID-19 and immune system defects as a result of their therapy and cancer itself ...
